Novel Materials for Viral Purification
Novel Materials for Viral Purification
批准号:
9408588
负责人:
BRADLEY T MESSMER
金额:
$22.42万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-09-01 至 2019-04-30
关键词:
AdenovirusesAffinityAreaAvidityBindingCancer VaccinesCapsid ProteinsCell Culture TechniquesCell TherapyCellsChromatographyColumn ChromatographyCommunicable DiseasesConcatenated DNACouplingDNADNA LibraryDependovirusDevelopmentDiseaseDivalent CationsExcisionExhibitsFiltrationFutureGene Transduction AgentGoalsImmobilizationIndividualLabelLibrariesMagnetismMalignant NeoplasmsMembraneMethodsModelingNucleic AcidsOligonucleotidesOncolyticPreparationProcessProductionProteinsProtocols documentationReagentRecoveryResidual stateSepharoseSingle-Stranded DNASourceSpecificityStreamStructureSubfamily lentivirinaeTechniquesTechnologyTestingViralViral VectorVirusViscosityWorkbasebioprocesscancer therapycommercial applicationcostfeedinggene therapyinterestmagnetic beadsmagnetite ferrosoferric oxidenanoparticulatenovelnucleaseoperationparticletoolvector
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Abstract
Viruses have significant commercial application as vectors for gene and cell therapy, as well as vaccines for
cancer treatment and infectious diseases. The purification of commercial viruses is a major area of bioprocess
development. Current methods are mostly based on filtration and chromatography, both of which scale poorly
and require clean feed streams to perform well. Viral particles are difficult to recover from culture supernatants
or cell lysates because they are similar in size to cell debris. A large amount of expensive, high-quality
nuclease (Benzonase) is typically needed to reduce the viscosity of the lysate sufficiently for efficient
membrane and column operations. Affinity based vector purification has been developed for only one type of
vector (some strains of adeno-associated virus), and is also very expensive. In summary, virus purification is
challenging and significant amounts of valuable product are lost in inefficient filters.
We have developed a novel DNA-based avidity reagent, termed DeNAno, that can provide a significant
advance in the development and manufacturing of commercial viruses, with applicability to a variety of viral
vectors. DeNAno uses massive avidity rather than affinity to capture biologic targets such as viruses. DeNAno
particles are composed of a single-stranded DNA concatemer, which contains several hundred copies of a
template oligonucleotide. The goal of this project is to develop DeNAno particles that bind to a target virus, and
then use the DeNAno as a capture reagent for virus purification. DeNAno libraries are produced by rolling
circle replication of a circular oligonucleotide template containing a random sequence, and specific viral
binders are recovered by a biopanning process. DeNAno particles can be released from their targets by
disrupting their secondary structure through divalent cation removal; they can also be labeled with nano-
particulate magnetite or coated onto micron-sized magnetite to allow their use as magnetic capture reagents.
We have already performed a selection on adenovirus-coated beads and obtained a pool of DeNAno particles
that bind the target virus. The specific aims of this project are to: 1) characterize DeNAno particles that bind to
the model virus (adenovirus) and 2) demonstrate their use as a purification tool by attaching them to magnetite
so that they can be used in magnetic capture. The virus will be released following capture by divalent cation
removal and the magnetic DeNAno cleared from the viral preparation, again by magnet. We will assess the
capture efficiency, virus yield and infectivity, residual DeNAno contamination, and the presence of host cell
proteins in the final preparation. If successful, this project will demonstrate the potential of the DeNAno
technology to streamline virus production and pave the way for additional DeNAno-based applications
targeting other commercially important viruses.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Personalized precision dosing of anti-TNF biologic therapies
-
批准号:9888300
-
项目类别:
-
资助金额:$84.11万
-
财政年份:2018
-
负责人:BRADLEY T MESSMER
-
依托单位:
Personalized precision dosing of biologic therapies in oncology
-
批准号:9984616
-
项目类别:
-
资助金额:$0.15万
-
财政年份:2017
-
负责人:BRADLEY T MESSMER
-
依托单位:
Activin A antagonist for treatment of cancer-associated cachexia
-
批准号:9046615
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:BRADLEY T MESSMER
-
依托单位:
Cleavage Coupled Lateral Flow Immunoassay for Rapid Endotoxin Testing
-
批准号:8905383
-
项目类别:
-
资助金额:$21.44万
-
财政年份:2015
-
负责人:BRADLEY T MESSMER
-
依托单位:
Multiplexed DeNAno Protein Assay and Quantitation: Sequencing Based Proteomics
-
批准号:8855369
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2015
-
负责人:BRADLEY T MESSMER
-
依托单位:
Lateral Flow Immunoassay for Therapeutic Monoclonal Antibody Quality Assurance
-
批准号:8648070
-
项目类别:
-
资助金额:$17.24万
-
财政年份:2014
-
负责人:BRADLEY T MESSMER
-
依托单位:
HMGB1-Derived Peptides As Vaccine Adjuvants
-
批准号:8435590
-
项目类别:
-
资助金额:$29.06万
-
财政年份:2012
-
负责人:BRADLEY T MESSMER
-
依托单位:
Molecular Evolution of Multifunctional DNA Nanoparticles
-
批准号:8293019
-
项目类别:
-
资助金额:$19.3万
-
财政年份:2011
-
负责人:BRADLEY T MESSMER
-
依托单位:
Molecular Evolution of Multifunctional DNA Nanoparticles
-
批准号:8472338
-
项目类别:
-
资助金额:$18.14万
-
财政年份:2011
-
负责人:BRADLEY T MESSMER
-
依托单位:
Molecular Evolution of Multifunctional DNA Nanoparticles
-
批准号:8035223
-
项目类别:
-
资助金额:$19.24万
-
财政年份:2011
-
负责人:BRADLEY T MESSMER
-
依托单位:
海外基金